Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer - Annals of Oncology
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet
Effect of Number of Treatment Cycles of Adjuvant Chemotherapy on Clinical Outcomes | Research To Practice
Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial | Nature Communications
HER2-Targeted Therapy for Early-Stage Breast Cancer: A Comprehensive Review
NCCP Chemotherapy Protocol Dose Dense Doxorubicin
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome | Nature Communications
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. - Abstract - Europe
Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052) | Scientific Reports
Chemotherapy for Uterus Cancer
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial - The Lancet Regional Health – Western Pacific
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer -
BreastCancerUpdate.com - Clinical Trials
Chemotherapy protocol definition form | Download Scientific Diagram
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose Densification - an overview | ScienceDirect Topics
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802) - Annals of Oncology
BIG against BC on Twitter: "#APHINITYtrial is a phase III adjuvant study investigating the benefit of pertuzumab when added to trastuzumab + # chemotherapy #SABCS19 #OncoAlert https://t.co/AkL68wNO02" / Twitter
AC Chemotherapy Regimen | Living Beyond Breast Cancer
Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel... | Download Table
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
1869-Breast neoadjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense | eviQ
